Adita Bio Sys Secures Global Accolades for Medical Device Testing

Pharmaids Pharmaceuticals' subsidiary, Adita Bio Sys Private Limited, has achieved a significant milestone by obtaining accreditation from the American Association for Laboratory Accreditation (A2LA).

This accreditation specifically covers the biological field for testing medical devices, enhancing Adita Bio Sys’s capabilities and aligning its services with international standards like ISO/IEC 17025:2017.

Reader Takeaway: Enhanced global credibility for testing services; parent company's financial performance remains a watchpoint.

What just happened (today’s filing)

Pharmaids Pharmaceuticals Limited announced on February 24, 2026, that its material subsidiary, Adita Bio Sys Private Limited, has successfully secured accreditation from the American Association for Laboratory Accreditation (A2LA).

This accreditation is targeted at the critical area of testing medical devices within the biological domain.

The recognition signifies Adita Bio Sys's adherence to high-quality standards and its competence in performing rigorous testing protocols.

Why this matters

The A2LA accreditation is globally recognised and ensures that Adita Bio Sys's testing methodologies and reports meet stringent international requirements. This elevates its standing in the competitive medical device testing market.

Compliance with standards such as ISO/IEC 17025:2017 and U.S. FDA Good Laboratory Practice (GLP) regulations can open new business avenues and strengthen relationships with domestic and international clients.

The backstory (grounded)

Pharmaids Pharmaceuticals, an integrated provider of Custom Research and Manufacturing Services (CRAMS), acquired a controlling stake of 99.86% in Adita Bio Sys Private Limited in 2024.

Adita Bio Sys has historically operated as a preclinical contract research organization (CRO) and has held various accreditations including GLP, NABL, and OECD certifications for its services. [15, 18]

Pharmaids Pharmaceuticals, however, has faced financial headwinds, reporting consistent net losses and low return on equity (ROE) in recent years, alongside a low interest coverage ratio. [16, 23]

What changes now

• Adita Bio Sys can now offer accredited testing services for medical devices, expanding its service portfolio and market reach.
• Enhanced credibility for Adita Bio Sys, potentially attracting more global clientele.
• Increased alignment with U.S. FDA GLP regulations, streamlining market access for clients whose devices are tested by Adita Bio Sys.
• The subsidiary's strengthened capabilities may bolster Pharmaids' overall service offerings in the contract research and testing space.

Risks to watch

• While Adita Bio Sys gains accreditation, Pharmaids Pharmaceuticals continues to grapple with financial challenges, including reported net losses and low profitability metrics. [16, 23]
• The medical device testing sector is competitive; maintaining accreditation and expanding services requires continuous investment and adherence to evolving global regulations.
• Dependence on the parent company's financial health could pose indirect risks to the subsidiary's growth trajectory.

Peer comparison

Adita Bio Sys's A2LA accreditation for medical device testing positions it alongside other key players in the preclinical CRO space. Maeon Life Science Laboratories in India also operates as an ISO/IEC 17025 accredited and CDSCO-approved GLP laboratory for medical device testing. [28]

Global players like Eurofins Scientific and SGS offer comprehensive analytical testing services, with many holding various international accreditations to serve the pharmaceutical and medical device industries. [37, 38, 40]

The A2LA accreditation specifically for biological testing of medical devices provides a competitive edge for Adita Bio Sys in specialized segments.

Context metrics (time-bound)

• Pharmaids Pharmaceuticals reported a revenue of ₹5.43 crore and a net loss of ₹2.08 crore in Q3 FY26. [3]
• Adita Bio Sys Private Limited, as a subsidiary, contributes to Pharmaids' overall revenue and profitability, though its specific financials are consolidated. [4, 13]

What to track next

• Any new client wins or contracts secured by Adita Bio Sys leveraging its A2LA accreditation.
• Developments in the integration of Adita Bio Sys's enhanced testing capabilities into Pharmaids' broader CRAMS offerings.
• Pharmaids Pharmaceuticals' efforts to improve its financial performance and profitability metrics.
• Regulatory updates in India concerning medical device testing and laboratory accreditations.
• The potential for Adita Bio Sys to expand its service scope or gain further accreditations in related fields.